Published in:
Open Access
01-12-2017 | Case report
Ticagrelor induced systemic inflammatory response syndrome
Authors:
Philipp Krisai, Manuel Haschke, Peter T. Buser, Christian Mueller
Published in:
BMC Cardiovascular Disorders
|
Issue 1/2017
Login to get access
Abstract
Background
Ticagrelor is a reversible and direct-acting oral antagonist of the adenosine diphosphate receptor P2Y12. Possible adenosine-mediated effects of ticagrelor on inflammation are complex and incompletely understood. To our knowledge, ticagrelor-induced systemic inflammatory response syndrome (SIRS) has not yet been described.
Case presentation
We report the case of an 84 years old patient presenting with SIRS subsequent to initiation of ticagrelor after implantation of two drug eluting stents. A broad diagnostic work-up for alternative causes and therapeutic measures were unrevealing. Discontinuation of the agent was followed by rapid improvement in clinical and laboratory signs of SIRS.
Conclusions
After exclusion of other causes, ticagrelor needs to be considered as a possible causative agent for SIRS. Due to the widespread use of ticagrelor, clinicians should be aware of this possible adverse drug reaction.